Appendix Table F-4. Study characteristics—KQ 4

| **Study** | **Study Design; Setting; Location;****Quality** | **Total N;****Interventions (N)** | **Mean Age** | **Type of AF: (Permanent, Paroxysmal, Persistent)** | **Mean Duration of AF** | **Special Popula-tion** | **HF** | **Mean LVEF (%)** | **CAD** | **Outcomes Assessed** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Alp, 2000[27](#_ENREF_27) | RCT;NR;UK;Fair | Total N: 59Arm 1: AL/AP (30)Arm 2: AP/AL (29) | Arm 1:67.8(SD 8.1)Arm 2:66.8(SD 7.9) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:23 wkArm 2:31 wk | Persistent AF | NR | Arm 1:52(SD 17)Arm 2:50(SD 12) | Arm 1:6NArm 2:3N | Restoration of sinus rhythm (conversion) |
| Capucci, 2000[1](#_ENREF_1) | RCT;Inpatient;Europe;Fair | Total N: 61Arm 1: Amiodarone (31)Arm 2: Digoxin (30) | Arm 1:59(SD 15)Arm 2:58(SD 10) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:16.3 wk(SD 6)Arm 2:18 wk(SD 5) | Persistent AF | NR | Arm 1:49 (SD 8)Arm 2:50 (SD 5) | Arm 1:4NArm 2:5N | Restoration of sinus rhythm (conversion), Recurrence of AF,Control of ventricular rate |
| Joglar, 2000[28](#_ENREF_28) | RCT;Outpatient;US;Good | Total N: 64Arm 1: DCC 100 (NR)Arm 2: DCC 200 (NR)Arm 3: DCC 360 (NR) | Total: 62(SD 11) | Total:0, 0, 100% | NR | Persistent AF | Total: 14N | NR | NR | Restoration of sinus rhythm (conversion) |
| Joseph, 2000[29](#_ENREF_29) | RCT;ER;Australia/NZ;Fair | Total N: 115Arm 1: Digoxin (36)Arm 2: Amiodarone (39)Arm 3: Sotalol (40) | Arm 1:64.9(SE 2)Arm 2:61.3(SE 2.6)Arm 3:62.8(SE 2.4) | NR | NR | None | NR | NR | Arm 1:3NArm 2:8NArm 3:7N | Restoration of sinus rhythm (conversion) |
| Villani, 2000[30](#_ENREF_30) | RCT;Outpatient;Europe;Fair | Total N: 120Arm 1: Diltiazem (46)Arm 2: Amiodarone (44)Arm 3: Digoxin (30) | Arm 1:59(SD 3)Arm 2:58(SD 7)Arm 3:56(SD 5) | Arm 1: 0, 0, 100%Arm 2: 0, 0, 100%Arm 3: 0, 0, 100% | Arm 1:18.0 wk(SD 5)Arm 2:16.3 wk(SD 6)Arm 3: 16 wk(SD 3) | Persistent AF | NR | Arm 1:50 (SD 5)Arm 2:49 (SD 8)Arm 3:52 (SD 5) | Arm 1:5NArm 2:4NArm 3:2N | Restoration of sinus rhythm (conversion), Recurrence of AF  |
| Ricard, 2001[31](#_ENREF_31) | RCT;NR;Europe;Fair | Total N: 57Arm 1: Monophasic (30)Arm 2: Biphasic (27) | Arm 1:69(SD 10)Arm 2:66(SD 12) | Arm 1:0, 2N, 0Arm 2:0, 2N, 0 | NR | None | NR | Arm 1:58 (SD 10)Arm 2:56 (SD 11) | Arm 1:6NArm 2:2N | Restoration of sinus rhythm (conversion) |
| Van Noord, 2001[32](#_ENREF_32)(VERDICT) | RCT;NR;Europe;Poor | Total N: 97Arm 1: Verapamil (48)Arm 2: Digoxin (49) | Arm 1:66(SD 13)Arm 2:66(SD 11) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:Median 18 daysArm 2:Median 21 days | Persistent AF | NR | NR | Arm 1:12NArm 2:8N | Restoration of sinus rhythm (conversion), Recurrence of AF  |
| De Simone, 2002[33](#_ENREF_33) | RCT;Inpatient;Europe; Poor | Total N: 88Arm 1: Verapamil + DCC (43)Arm 2: DCC (45) | Arm 1:60(SD 11)Arm 2:60(SD 12) | NR | Arm 1:94 days(SD 79)Arm 2:87 days(SD 65) | None | NR | Arm 1:50(SD 8.1)Arm 2:50 (SD 7) | Arm 1:6NArm 2:7N | Recurrence of AF  |
| Kirchhof, 2002[34](#_ENREF_34) | RCT;Outpatient;Europe;Good | Total N: 108Arm 1: AP (52)Arm 2: AL (56) | Arm 1:62(SD 2)Arm 2:58(SD 2) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:Median 5 mo(IQR, 0.1 to 120)Arm 2:Median 4 mo(IQR, 0.1 to 120 | Persistent AF | Arm 1:7NArm 2:13N | NR | Arm 1:13NArm 2:14N | Restoration of sinus rhythm (conversion) |
| Page, 2002[35](#_ENREF_35) | RCT;NR;US, Europe;Good | Total N: 203Arm 1: Monophasic (107)Arm 2: Biphasic (96) | Arm 1:65(SD 13)Arm 2:65(SD 14) | NR | NR | None | Arm 1:31%Arm 2:31% | NR | Arm 1:19%Arm 2:24% | Restoration of sinus rhythm (conversion) |
| Rashba, 2002[36](#_ENREF_36) | RCT;NR;US;Fair | Total N: 110Arm 1: Standard (55)Arm 2: Reverse (55) | NR | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | NR | Persistent AF | NR | NR | NR | Restoration of sinus rhythm (conversion) |
| Boos, 2003[37](#_ENREF_37) | RCT;NR;UK;Fair | Total N: 107Arm 1: Initial 360 DCC (50)Arm 2: Initial 200 DCC (57) | Arm 1:64.4(SD 10.5)Arm 2:67.7(SD 9.6) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | NR | Persistent AF | NR | NR | Arm 1:24%Arm 2:25% | Restoration of sinus rhythm (conversion) |
| Khaykin, 2003[38](#_ENREF_38) | RCT;Inpatient;Canada;Good | Total N: 56Arm 1: Monophasic (28)Arm 2: Biphasic (28) | Arm 1:59.7(SD 10.8)Arm 2:58.3(SD 14.6) | NR | Arm 1:26 wk(SD 19)Arm 2:24 wk(SD 18) | Previously failed a rate- or rhythm-control pharmaco-logical therapy strategy | NR | NR | NR | Restoration of sinus rhythm (conversion) |
| Manios, 2003[39](#_ENREF_39) | RCT;NR;Europe;Fair | Total N: 106Arm 1: Diltiazem (35)Arm 2: Amiodarone (34)Arm 3: Placebo (37) | Arm 1:64(SD 8)Arm 2:66(SD 7)Arm 3:62(SD 11) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100%Arm 3:0, 0, 100% | Arm 1:37 mo(SD 35)Arm 2:35 mo(SD 29)Arm 3:32 mo(SD 34) | Persistent AF | NR | Arm 1:61(SD 8.6)Arm 2:59(SD 6.3)Arm 3:62(SD 6.6) | Arm 1:4NArm 2:4NArm 3:2N | Restoration of sinus rhythm (conversion) |
| Marinsek, 2003[40](#_ENREF_40) | RCT;Outpatient;Europe;Fair | Total N: 83Arm 1: Monophasic (40)Arm 2: Biphasic (43) | Arm 1:67(SD 8)Arm 2:69(SD 6) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | NR | Persistent AF | NR | Arm 1:57(SD 11)Arm 2:56(SD 11) | Arm 1:8%Arm 2:14% | Maintenance of sinus rhythm |
| Scholten, 2003[41](#_ENREF_41) | RCT;NR;Europe;Fair | Total N: 227Arm 1: Monophasic (109)Arm 2: Biphasic (118) | Arm 1:59.9(SD 14)Arm 2:59.6(SD 12.4) | NR | Arm 1:Median 41 daysArm 2:Median 20.5 days | None | Arm 1:12NArm 2:11N | NR | Arm 1:6NArm 2:5N | Restoration of sinus rhythm (conversion) |
| Kanoupakis, 2004[42](#_ENREF_42) | RCT;Outpatient;Europe;Fair | Total N: 142Arm 1: Carvedilol (48)Arm 2: Amiodarone (48)Arm 3: Control (46) | Arm 1:66(SD 9)Arm 2:64(SD 8)Arm 3:61(SD 10) | Arm 1:0, 0, 100%Arm 2:0, 0, 100%Arm 3:0, 0, 100% | Arm 1:10 mo(SD 8)Arm 2:10 mo(SD 12)Arm 3:13 mo(SD 17) | Persistent AF | NR | Arm 1:60(SD 7.3)Arm 2:58(SD 5.6)Arm 3:57 (SD 9) | Arm 1:6NArm 2:5NArm 3:4N | Restoration of sinus rhythm (conversion), Recurrence of AF  |
| Lindholm, 2004[8](#_ENREF_8) | RCT;Outpatient;Europe;Fair | Total N: 100Arm 1: Digoxin (50)Arm 2: Verapamil (50) | Arm 1:72(SD 7)Arm 2:66(SD 10) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Total:8.4 moArm 1:7.5 mo(SD 6)Arm 2:10.7 mo(SD 8.5) | Persistent AF | NR | NR | NR | Control of ventricular rate, Maintenance of sinus rhythm,Restoration of sinus rhythm (conversion) |
| Rashba, 2004[43](#_ENREF_43) | RCT;NR;US;Fair | Total N: 120Arm 1: 20 DCC (30)Arm 2: 50 DCC (30)Arm 3: 100 DCC (30)Arm 4: 200 DCC (30) | Arm 1:65(SD 12)Arm 2:69(SD 13)Arm 3:65(SD 12)Arm 4:63(SD 10) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100%Arm 3:0, 0, 100%Arm 4:0, 0, 100% | Arm 1:71 days(SD 80)Arm 2:86 days(SD 100)Arm 3:136 days(SD 177)Arm 4:176 days(SD 371) | Persistent AF | NR | Arm 1:50(SD 16)Arm 2:41(SD 16)Arm 3:50(SD 13)Arm 4:50(SD 15) | Arm 1:33%Arm 2:30%Arm 3:33%Arm 4:27% | Restoration of sinus rhythm (conversion) |
| Siaplaouras, 2004[44](#_ENREF_44) | RCT;NR;Europe;Fair | Total N: 216Arm 1: Biphasic (NR)Arm 2: Monophasic (NR) | Arm 1:65(SD 10)Arm 2:66(SD 10) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:3.2 mo(SD 4)Arm 2:4.1 mo(SD 10) | Persistent AF | NR | Arm 1:62(SD 15)Arm 2:59(SD 13) | Arm 1:17%Arm 2:20% | Recurrence of AF, Restoration of sinus rhythm (conversion) |
| Thomas, 2004[9](#_ENREF_9) | RCT;ER;Australia/NZ;Fair | Total N: 140Arm 1: Amiodarone (52)Arm 2: Sotalol (45)Arm 3: Digoxin (43) | Arm 1:54.3(SD 15.9)Arm 2:57.7(SD 15.9)Arm 3:55.5(SD 16.5) | NR | NR | None | NR | NR | Total:15%Arm 1:7%Arm 2:4%Arm 3:4% | Restoration of sinus rhythm (conversion), Control of ventricular rate |
| Alatawi, 2005[45](#_ENREF_45) | RCT;Inpatient;US;Fair | Total N: 141Arm 1: Truncated (70)Arm 2: Rectilinear (71) | Arm 1:65.3(SD 14.5 )Arm 2:67.6(SD 12.9) | NR | NR | None | NR | Arm 1:53.9(SD 12.7)Arm 2:54 (SD 13) | Arm 1:20%Arm 2:32% | Restoration of sinus rhythm (conversion) |
| Kirchhof, 2005[46](#_ENREF_46) | RCT;Outpatient;Europe;Good | Total N: 201Arm 1: Steel (104)Arm 2: Adhesive (97) | Arm 1:63(SD 1)Arm 2:63(SD 1) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:8.1 mo(SD 2)Arm 2:4.5 mo(SD 0.2) | Persistent AF | NR | NR | Arm 1:36NArm 2:25N | Restoration of sinus rhythm (conversion) |
| Korantzo-poulos, 2005[47](#_ENREF_47) | RCT;Inpatient;Europe;Good | Total N: 100Arm 1: Ibutilide (51)Arm 2: Propafenone + ibutilide (49) | Total:65(SD 10)Arm 1:66(SD 9)Arm 2:65(SD 11) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Total:99 days(SD 92)Arm 1:98 days(SD 83)Arm 2:99 days(SD 100) | Persistent AF | NR | Arm 1:58 (SD 6)Arm 2:59(SD 10) | Arm 1:19%Arm 2:16% | Restoration of sinus rhythm (conversion) |
| Siaplaouras, 2005[48](#_ENREF_48) | RCT;NR;Europe;Fair | Total N: 123Arm 1: AP (60)Arm 2: AL (63) | Arm 1:67(SD 10)Arm 2:66(SD 10) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:3.0 mo(SD 5)Arm 2:3.8 mo(SD 9) | Persistent AF | NR | Arm 1:60(SD 13)Arm 2:59(SD 13) | Arm 1:10NArm 2:16N | Restoration of sinus rhythm (conversion), Recurrence of AF  |
| Singh, 2005[49](#_ENREF_49)(SAFE-T)Atwood, 2007[50](#_ENREF_50)Batcher, 2007[51](#_ENREF_51)Singh, 2009[52](#_ENREF_52) | RCT;Outpatient;US;Good | Total N: 665Arm 1: Amiodarone (267)Arm 2: Sotalol (261)Arm 3: Placebo (137) | Arm 1:67.1(SD 9.4)Arm 2:66.8(SD 8.9)Arm 3:67.7(SD 9.8) | NR | NR | None | Arm 1:67NArm 2:72NArm 3:33N | Arm 1:50.5(SD 12.4)Arm 2:51.5(SD 11.9)Arm 3:49.4(SD 12.7) | Arm 1:71NArm 2:66NArm 3:31N | Restoration of sinus rhythm (conversion)StrokeAll-cause mortalityRecurrence of AF  |
| Ambler, 2006[53](#_ENREF_53) | RCT;NR;UK;Fair | Total N: 128Arm 1: Monophasic (NR)Arm 2: Biphasic (NR) | Total:Median 70Min Age: 22Max Age: 87 | NR | NR | None | NR | NR | NR | Restoration of sinus rhythm (conversion) |
| Brazdzionyte, 2006[54](#_ENREF_54) | RCT;NR;Europe;Fair | Total N: 103Arm 1: AL (55)Arm 2: AP (48) | Arm 1:63.84(SD 11.67)Arm 2:62.31(SD 10.37) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | NR | Persistent AF | NR | Arm 1:48.6(SD 9.45)Arm 2:48.8(SD 6.08) | Arm 1:47.3%Arm 2:33.3% | Restoration of sinus rhythm (conversion) |
| Hemels, 2006[11](#_ENREF_11)(VERDICT) | RCT;NR;Europe;Fair | Total N: 144Arm 1: Digoxin (70)Arm 2: Verapamil (74) | Arm 1:65(SD 11)Arm 2:65(SD 8) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:140 daysArm 2:117 days | Persistent AF | Arm 1:7%Arm 2:5% | NR | Arm 1:19%Arm 2:12% | Control of ventricular rate, Restoration of sinus rhythm (conversion)Recurrence of AF,Maintenance of sinus rhythm,Quality of life/ Functional status |
| Hofmann, 2006[12](#_ENREF_12) | RCT;Inpatient;Europe;Good | Total N: 100Arm 1: Amiodarone (50)Arm 2: Digoxin (50) | Arm 1:68.3(SD 13)Arm 2:69.3(SD 13) | Total:0, 11%, 12%Arm 1:0, 12%, 10%Arm 2:0, 10%, 14% | NR | None | Total:12%Arm 1:16%Arm 2:8% | Arm 1:55.2(SD 19)Arm 2:54.3(SD 14) | NR | Control of ventricular rate, Restoration of sinus rhythm (conversion) |
| Mazzocca, 2006[55](#_ENREF_55) | RCT;NR;Europe;Fair | Total N: 50Arm 1: DCC (25)Arm 2: Ibutilide + DCC (25) | Arm 1:64(SD 14)Arm 2:69(SD 9) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:86 days (SD 79)Arm 2:84 days (SD 73) | Previously failed a rate- or rhythm-control pharmaco-logical therapy strategy, Persistent AF | NR | Arm 1:53 (SD 9)Arm 2:53(SD 10) | NR | Restoration of sinus rhythm (conversion) |
| Redfearn, 2006[56](#_ENREF_56) | RCT;NR;UK;Fair | Total N: 23Arm 1: Verapamil+DCC (9)Arm 2: DCC (14) | Arm 1:63.9 (SD 13.7)Arm 2:69.9 (SD 8.1) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:9.13 mo (SD 3.94)Arm 2:11.2 mo (SD 12.9) | Persistent AF | NR | NR | NR | Maintenance of sinus rhythm |
| Vijayalakshmi, 2006[57](#_ENREF_57) | RCT;NR;UK;Good | Total N: 94Arm 1: Control (31)Arm 2: Amiodarone (27)Arm 3: Sotalol (36) | Arm 1:64.8 (SD 9.1)Arm 2:65.5 (SD 10.5)Arm 3:62.8 (SD 9.3) | NR | Arm 1:7 mo(SD 4)Arm 2:6.6 mo(SD 3.9)Arm 3:7.3 mo(SD 4.4) | None | Arm 1:1NArm 2:1NArm 3:1N | Arm 1:40Arm 2:51Arm 3:40 | NR | All-cause mortality, Maintenance of sinus rhythm,Restoration of sinus rhythm (conversion) |
| Boodhoo, 2007[58](#_ENREF_58) | RCT;NR;UK;Fair | Total N: 261Arm 1: Initial 200J (125)Arm 2: 360 DCC (136) | Arm 1:70(SD 10)Arm 2:72(SD 10) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | NR | Persistent AF | Arm 1:6%Arm 2:1% | Arm 1:65Arm 2:65 | Arm 1:11%Arm 2:9% | Restoration of sinus rhythm (conversion), Maintenance of sinus rhythm,All-cause mortality,Mixed embolic events including stroke |
| Hassan, 2007[59](#_ENREF_59) | RCT;ER;US;Fair | Total N: 50Arm 1: Diltiazem (24)Arm 2: Esmolol (26) | Arm 1:62(SD 15)Arm 2:65(SD 15) | Arm 1:0, 8N, 0Arm 2:0, 11N, 0 | NR | None | NR | Arm 1:54.5(SD 14)Arm 2:50.5(SD 14) | Arm 1:4NArm 2:2N | Restoration of sinus rhythm (conversion), Control of ventricular rate |
| Kafkas, 2007[60](#_ENREF_60) | RCT;Inpatient;Europe;Fair | Total N: 152Arm 1: Ibutilide (79)Arm 2: Amiodarone (73) | Arm 1:62(SD 16)Arm 2:64(SD 18) | NR | NR | None | NR | Arm 1:53 (SD 6)Arm 2:52 (SD 8) | Arm 1:36NArm 2 :38N | Restoration of sinus rhythm (conversion), Recurrence of AF  |
| Kawabata, 2007[61](#_ENREF_61) | RCT;ER;S. America;Good | Total N: 154Arm 1: Biphasic (77)Arm 2: Monophasic (77) | Arm 1:55 (SD 13.5)Arm 2:60 (SD 13.3) | NR | NR | None | NR | NR | Arm 1:3NArm 2:10N | Restoration of sinus rhythm (conversion) |
| Nergardh, 2007[62](#_ENREF_62) | RCT;Outpatient;Europe;Good | Total N: 168Arm 1: Metoprolol + DCC (83)Arm 2: Placebo + DCC (85) | Arm 1:68.2 (SD 10.1)Arm 2:66.5 (SD 12.2) | Total:0, 0, 100%Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Arm 1:5.3 mo(SD 2.9)Arm 2:5.1 mo(SD 2.8) | Persistent AF | NR | Arm 1:48.6(SD 7.9)Arm 2:49.7(SD 6.7) | Arm 1:4NArm 2:3N | Control of ventricular rate, Maintenance of sinus rhythm,Restoration of sinus rhythm (conversion), All-cause mortality,Stroke |
| Glover, 2008[63](#_ENREF_63)(BEST AF) | RCT;Outpatient;UK;Good | Total N: 380Arm 1: Electrical cardioversion (low energy) (193)Arm 2: Electrical cardioversion (high energy) (187) | Total:67(SD 10)Arm 1:66.8 (SD 9.7)Arm 2:67.1 (SD 10) | Arm 1:0, 0, 100%Arm 2:0, 0, 100% | Total:Median 6.0 mo (IQR, 3 to 11)Arm 1:Median 6.0 mo (IQR, 4.0 to 12.0)Arm 2:Median 6.0 mo (IQR, 3.0 to 9.0) | Persistent AF | NR | Arm 1:52(SD 27)Arm 2:49(SD 29) | Arm 1:34%Arm 2:27% | Restoration of sinus rhythm |
| Mortensen, 2008[64](#_ENREF_64) | RCT;Inpatient, Outpatient, ER;Europe;Fair | Total N: 95Arm 1: Biphasic (48)Arm 2: Monophasic (47) | Total:62(SD 13)Arm 1:62(SD 12)Arm 2:62(SD 13) | NR | NR | None | NR | NR | Total:23.1%Arm 1:27%Arm 2:19.1% | Restoration of sinus rhythm (conversion) |
| Fragakis, 2009[65](#_ENREF_65) | RCT;Outpatient, ER;Europe;Fair | Total N: 90Arm 1: Esmolol + ibutilide (44)Arm 2: Ibutilide (46) | Total:63 (SD 13.5)Arm 1:63 (SD 11.5)Arm 2:63(SD 15) | Arm 1:0, 80%, 0Arm 2:0, 75%, 0 | Arm 1:16 days (SD 42)Arm 2:19 days (SD 30) | None | NR | Arm 1:63 (SD 6)Arm 2: 61 (SD 7) | Arm 1:11%Arm 2:9% | Restoration of sinus rhythm (conversion) |
| Balla, 2011[66](#_ENREF_66) | RCT;ER;Europe;Good | Total N: 160Arm 1: Flecainide (40)Arm 2: Amiodarone (40)Arm 3: Propafenone (40)Arm 4: Placebo (40) | Arm 1:57.9 (SD 9.5)Arm 2:58.9 (SD 10.4)Arm 3:57.4 (SD 9.8)Arm 4:58.6 (SD 10.7) | NR | Arm 1:16.2 hr (SD 9.1)Arm 2:19.1 hr (SD 12.4)Arm 3:18.6 hr (SD 4.2)Arm 4:17.8 hr (SD 13.9) | None | NR | NR | NR | Restoration of sinus rhythm (conversion) |

**Abbreviations:** Abbreviations: AF=atrial fibrillation; CAD=coronary artery disease; CV=cardiovascular; IQR=interquartile range; KQ=Key Question; LVEF=left ventricular ejection fraction; MI=myocardial infarction; mo=month(s); N=number of patients; NR=not reported; RCT=randomized controlled trial; SD=standard deviation